New drug combo takes on Hard-to-Treat cancers in first human trial
NCT ID NCT06108050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an investigational drug called JZP898, both by itself and together with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the combination can shrink tumors. About 177 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JZP898 (an investigational drug) and pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 177 participants, so the drug may not prove safe or effective. Side effects are unknown, and the combination with pembrolizumab could increase risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
California Cancer Associates for Research and Excellence
RECRUITINGEncinitas, California, 92024, United States
-
California Cancer Associates for Research and Excellence
RECRUITINGFresno, California, 93270, United States
-
Duke University Medical Center - Duke Cancer Institute
RECRUITINGDurham, North Carolina, 27710, United States
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Texas Oncology - Baylor Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States